-
FDA Gives Priority to Duchenne MD Therapy Golodirsen Review
The FDA is giving priority review to golodirsen, a potential Duchenne treatment for patients amenable to exon 53 skipping, Sarepta Therapeutics announced. Read more about this announcement here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.